{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:45:42Z","timestamp":1792154742535,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T00:00:00Z","timestamp":1532908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shire-U.S. Department of Veterans Affairs"},{"name":"CRADA"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI116635"],"award-info":[{"award-number":["AI116635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.antiviral.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T02:34:09Z","timestamp":1532140449000},"page":"128-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus"],"prefix":"10.1016","volume":"157","author":[{"given":"Sunwen","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Ercolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Derakhchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.07.013_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","article-title":"Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients","volume":"12","author":"Avery","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.013_bib2","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2S Suppl. 1","key":"10.1016\/j.antiviral.2018.07.013_bib3","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/TP.0000000000001777","article-title":"The role of mTOR inhibitors in the management of viral infections: a review of current literature","volume":"102","author":"Bowman","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.07.013_bib4","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.00186-10","article-title":"Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2011.01.004","article-title":"Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy","volume":"50","author":"Chou","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.07.013_bib6","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01325-17","article-title":"Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds","volume":"61","author":"Chou","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2016.12.003","article-title":"Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","volume":"138","author":"Chou","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.013_bib9","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1128\/JCM.00391-17","article-title":"Differentiated levels of ganciclovir resistance conferred by mutations at codons 591 to 603 of the cytomegalovirus UL97 kinase gene","volume":"55","author":"Chou","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.07.013_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.013_bib11","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/JVI.01787-07","article-title":"Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant","volume":"82","author":"Chou","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.013_bib13","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.49.7.2710-2715.2005","article-title":"Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene","volume":"49","author":"Chou","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib14","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/AAC.00207-06","article-title":"Effect of cell culture conditions on the anticytomegalovirus activity of maribavir","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1086\/518514","article-title":"Cytomegalovirus UL97 kinase mutations that confer maribavir resistance","volume":"196","author":"Chou","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.013_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP3028","article-title":"Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus","volume":"21","author":"Drouot","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.07.013_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-3542(02)00094-3","article-title":"Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus","volume":"56","author":"Evers","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.013_bib18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.07.013_bib19","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1128\/JVI.78.20.11030-11039.2004","article-title":"Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase","volume":"78","author":"Kudchodkar","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.013_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-385987-7.00004-X","article-title":"Regulatory roles of protein kinases in cytomegalovirus replication","volume":"80","author":"Marschall","year":"2011","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.antiviral.2018.07.013_bib21","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.07.013_bib22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.013_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Meth."},{"key":"10.1016\/j.antiviral.2018.07.013_bib24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/tid.12601","article-title":"Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients","volume":"18","author":"Pascual","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.013_bib25","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","article-title":"A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients","volume":"9","author":"Pescovitz","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.07.013_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.07.013_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.013_bib28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/1471-2334-13-330","article-title":"Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient","volume":"13","author":"Schubert","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.013_bib29","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1128\/AAC.47.4.1468-1471.2003","article-title":"Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication","volume":"47","author":"Selleseth","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.06.022","article-title":"Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies","volume":"145","author":"Smee","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.013_bib31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003088-200544080-00001","article-title":"Sirolimus: the evidence for clinical pharmacokinetic monitoring","volume":"44","author":"Stenton","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2018.07.013_bib32","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.48.5.1647-1651.2004","article-title":"Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus","volume":"48","author":"Underwood","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib33","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1128\/JVI.00192-14","article-title":"Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility","volume":"88","author":"Webel","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.013_bib34","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1128\/AAC.00114-15","article-title":"In vitro drug combination studies of letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication","volume":"59","author":"Wildum","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib35","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.013_bib36","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am. J. Transplant."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:06Z","timestamp":1759062426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218303061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":36,"alternative-id":["S0166354218303061"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.013","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}